Mycobacterium tuberculosis (MTB) microbiologic evidence, and misdiagnosis or delayed diagnosis often occurs as a consequence. We investigated the potential of lncRNAs and corresponding predictive models to diagnose these patients.
INTRODUCTION 1
Tuberculosis (TB) is the leading cause of death from an infectious agent 1 , but only 56% of 2 plmonary tuberculosis (PTB) cases reported to WHO in 2017 were bacteriologically 3 confirmed. Thus, approximately half of all PTB cases are clinically diagnosed worldwide, 4 and this proportion can reach 68% in China 1 . Clinically diagnosed PTB cases are 5 symptomatic but lack evidence of Mycobacterium tuberculosis (MTB) infection by smear 6 microscopy, culture or nucleic acid amplification test 1-3 . The diagnostic procedure for 7 clinically diagnosed PTB is inadequate and time-consuming and often results in misdiagnosis 8 or delayed diagnosis 3 , leading to an increased risk of morbidity and mortality 4 , or 9 overtreatment 5 . There is thus an urgent need to develop rapid and accurate strategies to 10 diagnose PTB cases without MTB microbiologic evidence 6, 7 . The exploration of effective 11 host immune-response signatures represents an attractive approach for this type of assay. 12
Long noncoding RNAs (lncRNAs) can function as critical regulators of inflammatory 13 responses to infection, especially for T-cell responses 8, 9 . Increasing evidence indicates that 14 blood lncRNA expression profiles are closely associated with TB disease [10] [11] [12] , suggesting 15 lncRNAs could function as potential noninvasive biomarkers for TB detection. However, 16
previous studies have suffered from small sample size (ranging from 66 to 510) and lack 17 independent validation. 18
Recent effort has focused on establishing clinical prediction rules or predictive models for 19 TB diagnosis based on patients' electronic health record (EHR) information [13] [14] [15] [16] . Such 20 models can cost-effectively facilitate PTB diagnosis with a limited number of clinical-21 radiological predictors. For example, a 6-signature model from Griesel et al. ( a cough lasting  22 ≥14 days, the inability to walk unaided, a temperature > 39°C, chest radiograph assessment, 23
hemoglobin level and white cell count) attained an AUC of 0.81 [0.80-0.82] in seriously ill 24
HIV-infected PTB patients 13 . However, despite these advances, current EHR models remain 25 6 insufficient for precise TB diagnosis. Compelling studies have proposed that models 26 incorporating biomarkers and EHR information attain better performance for prediction of 27 sepsis 17 and abdominal aortic aneurysm 18 . We previously reported that combining exosomal 28 microRNAs and EHRs in the diagnosis of tuberculous meningitis (TBM) achieved AUCs of 29 up to 0.97 versus an AUC of 0.67 obtained using EHR alone 19 . Based on these studies, we 30 hypothesized that combining lncRNAs with well-defined EHR predictors could be used to 31 develop improved predictive models to identify PTB cases that lack microbiologic evidence 32 of MTB infection. 33
This study was therefore performed to investigate the diagnostic potential of lncRNAs and 34 predictive models incorporating lncRNA and EHR data for the identification of PTB cases 35 without microbiologic MTB evidence. This study also explored the regulatory functions of 36 lncRNA candidates during MTB infection to evaluate the biological basis for their predictive 37 abilities. 38
39

MATERIAL AND METHODS 40
Study design 41
We performed this study through a four-stage approach. LncRNAs that were differentially 42 expressed (DE) between clinically diagnosed PTB patients and healthy subjects were profiled 43 by microarray in the Screening Step. The expression of top five lncRNAs were then analyzed 44 in a large prospective cohort in the Selection Step of the study, which reduced the number of 45 five lncRNAs to three based on expression difference among groups. In the Model Training 46
Step, lncRNAs and EHRs were used to develop predictive models for clinically diagnosed 47 PTB patients and non-tuberculosis disease control (non-TB DC) patients, and the optimal 48 model was visualized as a nomogram. Finally, we validated lncRNAs and the nomogram in 49 an independent prospective cohort. Functional analyses were also performed to elucidate the 50 biological significance of lncRNAs. The study strategy is shown in Figure 1 . 51
Subjects enrolment 52
Screening Cohort We retrospectively collected age-and gender-matched 7 PTB cases and 5 53 healthy controls as the Screening Cohort. They were 6 males and 6 females from ages 22 to 54 59 years. PTB cases were clinically confirmed PTB patients with positive TB symptoms, 55 negative MTB pathogenic examinations, and good response to anti-TB therapy. Healthy 56 subjects had a normal physical examination and no history of TB. 57 were evaluated spectrophotometrically, and RNA integrity was determined using agarose gel 85 electrophoresis (e- Figure 1A ). The PrimeScript TM RT reagent Kit with gDNA Eraser (Takara, 86 Japan) was used to remove contaminating genomic DNA and synthesize cDNA. Diagnostic modeling Multivariable logistic regression was used to develop predictive models 108 to distinguish clinically diagnosed PTB from patients with suspected PTB cases in the 109 Selection Cohort. Feature subsets were selected and compared using the best subset selection 110 procedure 23 and 10-fold cross-validation. The "EHR+lncRNA", "lncRNA only" and "EHR 111 only" models were developed according to their respective best feature subset in the Selection 112 Cohort. A cutoff of each model was determined by combining the Youden's index and the 113 sensitivity for the samples in the training dataset equal to or greater than 0.85. The models 114 including their cutoff were used for evaluation of the Validation Cohort. 115
Selection Cohort and Validation Cohort
Nomogram presentation and evaluation
We further adopted the nomogram to visualize the 116 optimal model with the best AUC 24, 25 . Nomogram calibration was assessed with the 117 calibration curve and Hosmer-Lemeshow test (p-value > 0.05 suggested no departure from 118 perfect fit). The performance of the nomogram was tested in the independent Validation 119 Cohort, with total points for each patient calculated. Decision curve analysis (DCA) 25 was 120 performed by evaluating the clinical net benefit of the nomogram and "EHR only" model 121 10 across the overall datasets. Assessing clinical value involves comparing the nomogram and 122 "EHR only" model using the 500 bootstrap method. The nomogram was implemented as a 123
Web-based app using R Shiny. 124
Analysis of ENST00000497872 (lnc AL) function 125
The lncRNA with the most significant difference in our analysis, ENST00000497872 (lnc AL) 126 was analyzed in functional studies. THP-1 cells with stable overexpression and knockdown 127 of lnc AL were constructed using recombinant lentivirus vector (LV). THP-1 cells transfected 128 with these vectors were incubated with Bacillus Calmette-Guerin (BCG) to imitate active 129 MTB-infection 26 Cohorts are provided in Table 1 . PTB patients were younger and had greater IGRA positivity 149 rates than their non-TB DC (p-value < 0.0001 for both the Selection and Validation Cohorts), 150 but these groups did not differ by gender, BMI, or smoking status. Healthy subjects were age-, 151 gender-, and BMI-matched with PTB patients, who had significantly different blood test 152 results compared with PTB patients (Table 1) . 153
Clinically diagnosed PTB patients were responsible for 29.82% (238/798) of all active 154 PTB patients (see e-Appendix 1). This rate is markedly lower than a nationwide estimate of 155 68% based on primary public health institutions 1 , but represents the clinically diagnosed 156 PTB rate in a referral hospital with experienced specialists. 157
LncRNAs microarray profiles and candidate selection 158
In the Screening Step, microarray profiling identified a total of 325 lncRNAs that were 159 differentially expressed (287 upregulated and 38 downregulated) in the clinically diagnosed 160 PTB patients versus healthy subjects. Hierarchical clustering and a volcano plot revealed 161 clearly distinguishable lncRNA expression profiles (e- Figure 2 ). Top five lncRNA candidates 162 were chosen based on a set of combined criteria: fold-change > 2 between groups, p-value < 163 0.05, signal intensity > 25 27 , and including unreported lncRNAs in TB literature 28 . Three of 164 these five lncRNAs were upregulated (n335265, ENST00000518552 and TCONS_00013664) 165 and two were downregulated (n333737 and ENST00000497872) in PTB versus control 166 subjects (e- Table 3) . 167
Differentially expressed lncRNAs in clinically diagnosed PTB
12
The expression level of these five candidate lncRNAs was measured by qRT-PCR in the 169 Selection Cohort, which consisted of 141 clinically diagnosed PTB, 159 non-TB DC, and 578 170 healthy subjects. Two lncRNAs (ENST00000518552 and TCONS_00013664) were excluded 171 from further analysis due to their low abundance expression (Cq > 35) in this cohort. Of the 172 three remaining lncRNAs, ENST00000497872 and n333737 were downregulated and 173 n335265 was upregulated in PTB patients versus healthy subjects (e- Table 4 ). Comparison 174 between clinically diagnosed PTB cases and non-TB DC patients revealed a decreased 175 expression of ENST00000497872 and n333737 in PTB patients (e- Figure 3A) , age-adjusted 176 p-values both < 0.0001). 177 Short-term stability, an essential prerequisite of a potential lncRNA biomarker, was 178 assessed in PBMC samples. This study found that incubation up to 24 h had minimal effect 179 on the expression of ENST00000497872, n333737, and n335265 (e- Table 5 ), in accordance 180 with a previous report of lncRNA stability in blood 29 . 181
Diagnostic modeling and nomogram visualization 182
Three logistic regression models, "EHR+lncRNA", "EHR only", and "lncRNA only" were 183 evaluated as part of the training step in the Selection Cohort (see e-Appendix 4). The variance 184 inflation factors between the features ranged from 1.02 to 1.29, indicating no collinearity 185 within models. The "EHR+lncRNA" model yielded the highest AUC (0.92) for 186 distinguishing clinically diagnosed PTB from suspected PTB patients, compared to AUCs of 187 0.87 and 0.82 for the "EHR only" and "lncRNA only" models, respectively (Figure 2A ). The 188 "EHR+lncRNA" model also had the best performance in sensitivity, specificity, accuracy, 189 positive predictive value, and negative predictive value ( Table 2) . 190
The optimal "EHR+lncRNA" model was displayed as a nomogram ( Figure 3A) , and the 191 top five features of the nomogram were ENST00000497872, age, n333737, CT calcification, 192 and TB-IGRA results (e- Table 6 ). Seneitivity and specificity of the nomogram for prediction 193 13 of clinically diagnosed PTB was 0.89 (0.82-0.93) and 0.80 (0.73-0.85) at a cutoff of 0.37 194 (Table 2) . A calibration curve in the Selection Cohort ( Figure 3B ) indicated a good 195 agreement between nomogram prediction and actual PTB cases and was confirmed by the 196 nonsignificant Hosmer-Lemeshow test (p-value = 0.957). This nomogram was generated as a 197 free online app (available at https://xuejiao.shinyapps.io/shiny/) to facilitate its access for 198 other studies. This app allows the user to insert the values of specific predictors and provides 199 the risk prediction as a whole number percentage. 200
Validation for lncRNAs and the nomogram 201
In the Validation Step, the three candidate lncRNAs were analyzed in an independent 202
Validation Cohort contains 97 clinically diagnosed PTB cases, 140 non-TB DC and 245 203 healthy subjects. This analysis observed an lncRNA expression pattern similar to that 204 observed in the Selection Cohort (e- Table 4 , e- Figure 3B ). All three models were applied to 205 the Validation Cohort, and as reported in Table 2 that the nomogram outperformed the conventional "EHR only" model with a higher clinical 211 net benefit within a threshold probability range from 0.2 to 1 ( Figure 3C ). 212
LncRNA response to anti-TB treatment 213
LncRNAs were next analyzed for the ability to predict anti-TB treatment response. Paired 214 samples were collected from 22 clinically diagnosed PTB patients before and after 2-month 215 intensive therapy 30 , and the expressions of ENST00000497872, n333737, and n335265 were 216 measured by qRT-PCR. All these patients had good response to therapy based on the clinical 217 14 and radiological findings, and ENST00000497872 and n333737 levels significantly increased 218 post-treatment (p-values = 0.005 and 0.0005, respectively, Figure 4 ), suggesting that lncRNA 219 expression increased in response to therapy. 220
Functional studies of ENST00000497872 221
We investigated whether ENST00000497872 (i.e., lnc AL) could affect the host immune The present work focused on the challenge of accurately diagnosing PTB patients without 231 microbiological evidence of MTB infection. Our study showed that three lncRNAs 232 (ENST00000497872, n333737, and n335265) were potential biomarkers for clinically 233 diagnosed PTB patients. Addition of three lncRNAs (ENST00000497872, n333737 and 234 n335265) to a conventional EHR model improved its ability to identify PTB cases from TB 235 suspects, with the AUCs increasing from 0.83 to 0.89. The lncRNA that was most 236 significantly enriched in the PTB group of this study, ENST00000497872 (chr14:105703964-237 105704602), is located close to IGHA1 (chr14: 105703995-105708665), and functional 238 analyses indicated that expression of this lncRNA was involved in the regulation of 239 inflammatory cytokine production and cell apoptosis in MTB-infected macrophages, 240 15 although further studies are needed to investigate the mechanisms responsible. Consistent 241 with published lncRNA data [8] [9] [10] [11] [12] 31 , this data provide new evidence that lncRNAs could 242 participate in TB immunoregulation and serve as promising biomarkers for TB diagnosis. 243
In addition to the three lncRNAs, we identified six EHR predictors (age, CT calcification, 244 positive TB-IGRA, low-grade fever, elevated hemoglobin, and weight loss) that were 245 essential in TB case finding, as proposed by prior findings 15, 16 . Age was an important 246 negative predictor for clinically diagnosed PTB, which appears to conflict with the consensus 247 that advanced age correlates with higher TB susceptibility 32 . This may be explained by 248 differences in the enrollment of the PTB patients and control subjects. Previous studies 249 included healthy and/or vulnerable subjects as controls, while we enrolled inpatients with a 250 wide range of pulmonary diseases and older ages as disease controls. 251
This study serves as a first proof-of-concept study to show that integrating lncRNA 252 signatures and EHR data could be a more promising diagnostic approach for PTB patients 253 with negative MTB pathogenic evidence. The "EHR+lncRNA" model had good 254 discrimination (through AUC and diagnostic parameters), reliable calibration (via calibration 255 curve and Hosmer-Lemeshow test), and potential clinical utility for decision-making (using 256 DCA). The "EHR+lncRNA" model avoided some common problems associated with 257 sputum-based features, such as poor sputum quality or problematic sampling 33 , to improve 258 its reliability and clinical utility. Nomogram has been shown to remarkably promote early 259 diagnosis of intestinal tuberculosis 24 and prognosis prediction in PTB 34 and TBM 35 . 260 "EHR+lncRNA" model herein was visualized as a nomogram and further implemented in an 261 app. The online nomogram uses readily obtainable predictors and automatically outputs a 262 personalized quantitative risk estimate for PTB. Utilizing this user-friendly tool may facilitate 263 the rapid identification of PTB cases among suspected TB patients without MTB 264 16 microbiologic evidence to improve TB diagnosis, especially in resource-constrained areas 265 with high TB prevalence. 266
Our study has several limitations. Modeling in this study was conducted based on data 267 from a single large hospital, and multi-center validation studies are needed. Further, because 268
Xpert MTB/RIF is still not routinely available in most clinical laboratories of China, and 269 since previous Xpert studies reported moderate sensitivities ranged from 28% to 73% [36] [37] [38] in 270 smear-negative PTB patients, we did not consider Xpert in our research, which may limit the 271 generalization of our findings. 272
In summary, a novel nomogram we developed and validated in this study that incorporated 273 three lncRNAs and six EHR fields may be a useful predictive tool in identifying PTB patients 274 with negative MTB pathogenic evidence, and merits further investigation. LncRNA expressions before (blue) and after (red) a 2-month intensive anti-TB treatment regimen. Altered lncRNA expressions were calculated using log 2 lncRNA (post-treatment expression / pre-treatment expression) and the Wilcoxon matched-paired rank test was used for comparisons among 22 paired samples.
The median and interquartile range of log 2 lncRNA were as follows: ENST00000497872 (before: - 
